Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Treatment of subsyndromal depressive symptoms in middle-age and older patients with schizophrenia: effect of age on response.
OBJECTIVE The authors hypothesized that age would moderate the response of patients with schizophrenia and subsyndromal depression ( SSD ) treated citalopram with depressive symptoms and other outcomes . Also , older patients would exhibit more side effects with citalopram . METHODS Participants of 40 years or older had schizophrenia or schizoaffective disorder with SSD . Patients r and omly received flexible dosing of citalopram or placebo augmentation of their antipsychotic medication . Linear regression determined whether age had any moderating effect on depressive symptoms , global psychopathology , negative symptoms , mental functioning , and quality of life . Age-related side effects were examined . RESULTS There were no significant drug group by age interaction in depressive or psychotic symptoms , mental Short Form-12 , or quality of life scores . Similarly , there were few age-related side effect differences . CONCLUSION Symptoms in younger and older patients with schizophrenia and SSD treated with citalopram seem to respond similarly . Adverse events do not seem to differ with age
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .